Search

Search Constraints

You searched for: Author/Creator Papadopoulos, Kyriakos P

Search Results

1. A Phase I study to evaluate the safety and antitumor activity of durvalumab (MEDI4736) in combination with tremelimumab in patients with advanced solid tumors. (4th November 2015)

2. CD8+ T cell stimulation with pegylated recombinant human IL-10 in the patient with advanced solid tumors - a Phase I study. (4th November 2015)

3. Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial. Issue 11 (November 2019)

4. Phase I study of anti-epidermal growth factor receptor antibody-drug conjugate serclutamab talirine: Safety, pharmacokinetics, and antitumor activity in advanced glioblastoma. Issue 1 (21st December 2022)

5. Preclinical investigations and a first-in-human phase I trial of M4112, the first dual inhibitor of indoleamine 2, 3-dioxygenase 1 and tryptophan 2, 3-dioxygenase 2, in patients with advanced solid tumors. Issue 2 (24th August 2020)

6. Preclinical investigations and a first-in-human phase I trial of M4112, the first dual inhibitor of indoleamine 2, 3-dioxygenase 1 and tryptophan 2, 3-dioxygenase 2, in patients with advanced solid tumors. Issue 2 (24th August 2020)

7. Preclinical investigations and a first-in-human phase I trial of M4112, the first dual inhibitor of indoleamine 2, 3-dioxygenase 1 and tryptophan 2, 3-dioxygenase 2, in patients with advanced solid tumors. Issue 2 (24th August 2020)

8. Preclinical investigations and a first-in-human phase I trial of M4112, the first dual inhibitor of indoleamine 2, 3-dioxygenase 1 and tryptophan 2, 3-dioxygenase 2, in patients with advanced solid tumors. Issue 2 (24th August 2020)

9. Preclinical investigations and a first-in-human phase I trial of M4112, the first dual inhibitor of indoleamine 2, 3-dioxygenase 1 and tryptophan 2, 3-dioxygenase 2, in patients with advanced solid tumors. Issue 2 (24th August 2020)

10. Preclinical investigations and a first-in-human phase I trial of M4112, the first dual inhibitor of indoleamine 2, 3-dioxygenase 1 and tryptophan 2, 3-dioxygenase 2, in patients with advanced solid tumors. Issue 2 (24th August 2020)